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INTRODUCTION 
Essentially none of the large-molecule pharmaceutics (e.g. 
peptides, proteins and nucleicacids) can enter the brain, 
and over 98% of small molecule drugs cannot enter the 
braineither1. In the past years, several methods to study 
brain uptake of drugs have been developed. To enhance 
brain uptake, nanoparticles have been used to target drugs 
to thebrain. Nanoparticles are different from CNS 
compounds in size, composition and uptake mechanisms. 
This has led to different methods and approaches to study 
brain uptake in vivo. Here we discuss the techniques 
generally used to measure nanoparticle uptake in addition 
to the techniques used for CNS compounds. 
Drug transport at the blood-brain barrier 
Transport from the blood to the brain is limited by the 
blood-brain barrier (BBB). The BBBis formed by brain 
endothelial cells that line the cerebral microvessels. It is 
supported byother cell types surrounding the endothelium, 
such as astrocytes and pericytes2. These surrounding cells 
contribute to the induction of many barrier characteristics 
of theendothelium, such as tight junctions, that closely join 
the endothelial cells together. Next to being a “physical 
barrier”, the BBB is also a “transport barrier”. This aspect 
is formed byspecific transport proteins and transcytosis 
mechanisms that mediate the uptake and efflux of 
molecules. Thirdly, a “metabolic barrier” is formed by the 
expression of metabolizing enzymes such as peptidases, 
cytochrome P450 enzymes, and monoamine oxidases3-5. 
All of these barrier functions control and regulate both 
inward and outward transfer of molecules between blood 
and the brain. 
ROUTES FOR THE TRANSPORT OF MOLECULES 
ACROSS THE BBB   
Paracellular hydrophilic diffusion:Paracellular transport 
of hydrophilic molecules is highly restricted by the tight 
junctions present between brain endothelial cells. 
Transcellular lipophilic diffusion: Lipid soluble 
molecules with molecular weights below 400 Da are able 
to cross by transcellular lipophilic diffusion, provided that 
they are not bound to plasma proteins to a high extent, or 
form a substrate for a transport system at the BBB. Based 
on physicochemical properties such as molecular weight 
and hydrogenbonding,predictions can be made whether a 
compound can cross the BBB via this route6,7. 
Receptor mediated endocytosis:For a variety of 
molecules that are essential for brain function, such as 
amino acids, glucose, peptides, and proteins, specific 
endogenous BBB transporters exist. These are expressed at 
both the luminal and the basolateral membranes of the 
endothelium8.These transporters can be either defined as 
carriers or receptors. 
Carrier mediated transcytosis:Carriers are membrane-
restricted systems. They are generally responsible for the 
transport of small molecules with a fixed size and mass 
smaller than 600 Da. Carrier-mediated transcytosisare used 
for the delivery of nutrients such as glucose, amino acids, 
and purine bases to the brain. It is substrate selective and 
only drugs that closely mimic the endogenous carrier 
substrates will be taken up9. 
Adsorptive mediated endocytosis:Endocytosis at the 
BBB is effectuated through adsorption or receptor binding. 
Adsorptivemediated endocytosis is initiated by the binding 
of polycationic substances to negative charges on the 
plasma membrane9. Receptor-mediated endocytosis is 
initiated by the binding of a receptor-specific ligand. 
Following adsorption or binding, the substance is 
internalized and transported via the early endosome to the 
lysosome, or transcytosed to the plasma membrane. The 
only way for larger molecules and particles such as 
antibodies, lipoproteins, proteins and nanoparticles to be 
transported into the brain is via receptor or adsorptive-
mediated endocytosis10, which is different from small 
molecular weight CNS drugs. When compared to the 
peripheral endothelium, the cerebral endothelium has a 
much lower endocytotic and transcytotic activity, making 
BBB-passage of larger molecules difficult even when 
ABTRACT 
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endocytosis is possible. In pathological conditions, the 
transport mechanism at the BBB might be up or down 
regulated1. 
Efflux pump:Next to these influx systems, many efflux 
mechanisms exist at the BBB as well. These include P-
glycoprotein, MDR-related protein, ABC transporters, and 
several others 1.They restrict entry of molecules into the 
brain by promoting luminal release of compounds, and are 
important in removing harmful substances from the brain, 
thereby reducing toxic side effects of CNS drug 
metabolites. Substrates for efflux transporters include 
peptides,lipids, cholesterol, hormones, CNS drugs, and 
metabolites11. 
PATHWAYS ACROSS THE BLOOD-BRAIN 
BARRIER  
After in vivo administration, most CNS drugs will enter 
the brain in their free form via transcellular diffusion. 
However, many compounds with psychopharmacological 
activity do not possess the right physicochemical 
characteristics to be able to cross the BBB. One possible 
way to mask these characteristics is to package these 
compounds in nanoparticles. Nanoparticles are, of course, 
much larger and are only able to enter the brain endothelial 
cells via adsorptive or receptor-mediated endocytosis. 
Subsequent transcytosis to the basal side of the brain 
endothelial cells is required to enter into the brain 
parenchyma2. After a drug or nanoparticle formulation has 
been administered, the concentration that can be measured 
in the brain depends on several factors. Theseinclude:5,13 
 the plasma concentration-time curve 
 the extent of plasma protein binding 
 the permeability across the BBB 
 the efflux out of the brain by efflux transporters 
 the metabolic conversion by enzymes 
 the binding to membranes or intracellular sites in the 
brain  
 the continual secretion and drainage of cerebrospinal 
fluid (CSF)  
 brain interstitial fluid (ISF) 
IN VIVO TECHNIQUES TO MEASURE 
COMPOUND PERMEATION INTO THE BRAIN   
A number of in vivo techniques have been developed to 
measure the uptake of CNS drugs into the brain. 
Kin and PS product determination by intravenous 
injection 
The intravenous injection technique is regarded as the gold 
standard for brain uptake studies, because it involves fully 
physiological conditions14,17. With this technique, a 
(radiolabeled) compound is injected intravenously. Blood 
is sampled at various time points. The main advantages of 
the iv injection method are the ease of injection, the 
possibility to simultaneously measure pharmacokinetics, 
and the fully physiological conditions, enabling all 
transporters, junction proteins, and enzymes to be present 
at their physiological concentration. 
Kin and PS product determination by in situ perfusion 
The in situ perfusion method complements the iv injection 
method. It has been originally developed for rats, but it has 
been expanded for mice, guinea pigs, and rabbits
18,20
. The 
main advantages of the in situ perfusion method are the 
ability to tailor the perfusion fluid, the constant infusion 
concentration, and the absence of compound metabolism 
in other organs 17,22.  
Brain uptake index (BUI) 
The brain uptake index (BUI), represents the relative 
uptake of a drug compared to a reference substance25,26. 
The reference is freely diffusible across the BBB, such as 
14C-butanol. The test compound is also radiolabeled, for 
example with 3H. The main advantage of the BUI 
technique is that it is fast while its main disadvantage is the 
low sensitivity. Additionally, drugs that are taken up 
slowly cannot be studied with this method14. Examples of 
BUI values obtained in vivo are 1.4% for sucrose, and 
90% for caffeine24. 
Quantitative autoradiography 
Quantitative autoradiography can be used to determine the 
amount of radioactive test compound in specific regions of 
the brain, such as stroke-affected areas29 or brain tumors30, 
following oral, intravenous or subcutaneous administration 
to small animals. The strength of quantitative 
autoradiography lies in the high spatial resolution in the 
micrometer range 14,31. 
Microdialysis 
Intracerebralmicrodialysis involves the implantation of a 
microdialysis probe in the brain. The probe, which consists 
of a semipermeable membrane, is continuously perfused 
with a physiological solution. The test drug is administered 
to the animal by the desired route (e.g. oral, intravenous or 
subcutaneous). Drugs that cross the BBB and enter the 
brain interstitial fluid can traverse the semipermeable 
membrane by diffusion into the physiological buffer. The 
buffer is sampled from the probe, and drug concentration 
is measured. The concentration in the sample reflects the 
concentration of free drug in the brain. The main 
advantage of microdialysis is that brain levels, as well as 
blood levels of the drug can be determined at many time 
points in one animal. From these data, pharmacokinetic 
parameters can be obtained. Drawbacks include the 
technical difficulties of the implantation, and the fact that 
highly lipophilic compounds are generally difficult to 
recover32. 
Brain/plasma ratio  
Commonly used in the pharmaceutical industry is the 
brain/plasma ratio33. The test drug is administered to the 
animal by the desired route. At a predetermined time point, 
the blood is sampled and the brain is taken out. The brain 
is homogenized and the drug concentration is determined 
in both brain and plasma. If multiple animals were used for 
multiple time points, the AUC of both the brain and 
plasma can be obtained. The brain concentration is then 
divided by the plasma concentration. This can be the ratio 
of one time point or the ratio of the AUCs34. The ratio 
provides a measure of the extent of brain penetration, not 
of the rate of brain penetration. Usually, the presence of 
drug remaining in the brain vasculature is not taken into 
account. 
External detection methods  
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The techniques described so far involve sampling from the 
brain. Next to these invasive techniques, several non-
invasive external imaging techniques exist, including 
positron emission tomograpy (PET), and single photon 
emission computed tomograpy (SPECT). It has been 
shown that PET can be used to quantitatively measure the 
PS product
35
. However, PET and SPECT are in general 
used for imaging of transporters, receptors, inflammation, 
or tumors in the brain, and not for the uptake of 
compounds36-38. 
CNS COMPOUNDS VERSUS NANOPARTICLES 
As the vast majority of potential CNS compounds have 
limited brain uptake, they may benefit from the use of 
advanced delivery systems in order to cross the BBB. 
Nanoparticles have been widely used as drug carriers to 
increase uptake of such drugs into the brain. The drug is 
encapsulated in, or associated to the particle, thereby 
masking its physiochemical characteristics. Particles that 
have been used include liposomes, solid lipid 
nanoparticles, nanogels, dendrimers, albumin 
nanoparticles, and polymeric particles such as poly(lactic-
co-glycolic acid) (PLGA) and poly(butyl cyanoacrylate) 
(PBCA) nanoparticles. In many cases, they are combined 
with targeting ligands on the particle surface to enhance 
uptake. Ligands can include peptides, proteins, and 
antibodies. 
IN VIVO TECHNIQUES TO MEASURE 
NANOPARTICLE UPTAKE INTO THE BRAIN   
The design of brain uptake studies of free drugs is 
generally different from the design of brain uptake studies 
of nanoparticles, because the size, physicochemical 
properties, and uptake mechanisms are different. This 
results in different approaches. The methods that have 
been used for brain targeting studies using nanoparticles in 
the past decade are described here. 
Visualization methods 
Microscopy is the most widely used qualitative method to 
study BBB uptake of nanoparticles in vivo. 
Fluorescence microscopy 
Fluorescence microscopy is often used for its sensitivity. It 
requires loading of the nanoparticles with a fluorescent 
dye51, or covalent coupling of the particle building blocks 
to a dye49. Commonly used fluorescent dyes include 
rhodamine-123, fluorescein, and 6-coumarin. Particles are 
usually injected iv, and aftersectioning the brain, they can 
be localized using fluorescence microscopy. The brain 
endothelium can be visualized by using an endothelium 
staining marker such as lectin. If such a marker is included 
in the staining procedure, a distinction can be made 
between particles that are associated with the brain 
endothelium, and particles that have crossed into the brain 
parenchyma53. If gene delivery to the brain is of interest, a 
plasmid expressing a fluorescent protein can be 
incorporated intothe particle, and gene expression can be 
assessed by visualizing protein fluorescence in the brain 
sections48. 
Electron microscopy 
Electron microscopy is commonly used. With this 
technique,single particles can be visualized in specific 
regions of the brain. 
Behavioral tests  
Some drugs that act on the CNS are unique compared to 
drugs that act on any other organ, because of their ability 
to interfere with brain signaling, and to induce specific 
behavioral effects. This gives rise to the possibility of not 
only detecting the level of compound that reaches the 
brain, but also to determine whether the compound has a 
pharmacodynamic effect. Drugs that normally do not enter 
the brain can be encapsulated into nanoparticles, to be 
transported over the BBB. The effect of the drug in the 
brain can be read out by monitoring the behavior of the 
animal, with specifically designed behavioral tests. These 
tests do not register the whole particle inside the brain, but 
only the free drug that has been released from the particle, 
as only the free drug will be able to exert an effect. Drug 
release from nanoparticles at the site of interest is crucial; 
therefore behavioral tests are of great value. 
Nociceptive tests  
A common model drug that has been used in combination 
with nanoparticles is the opiate antagonist loperamide. 
Intracerebral administration of loperamide causes 
antinociceptive effects. However, after iv injection of 
loperamide, these effects are not seen. This is due to the 
efflux membrane transporter P-glycoprotein54. 
Loperamidemolecules that reach the endothelial cells of 
the blood-brain barrier are rapidly transported back to the 
blood circulation. Therefore, loperamide is not able to 
enter into the brain parenchyma, making it a model drug 
for nociceptive testing. It can be loaded inside 
nanoparticles50, or simply be adsorbed onto the surface of 
the particles44.Loperamide-containing particles that are 
successfully taken up by the brain, can release their drug 
content in the brain, causing an analgesic effect of 
loperamide after ivadministration46. Similar to loperamide, 
the hexapeptidedalargin has been used for this purpose 52. 
Motor function and learning & memory tests  
Other models that allow for behavioral testing often 
include induction of disease states in animals, like MPTP-
induced Parkinson syndrome. Drugs that treat these 
syndromes, but normally do not penetrate the BBB in their 
free form, are candidates for nanoparticle formulation to 
enhance brain uptake. An example is nerve growth factor 
(NGF)40. NGF has been evaluated for the treatment of 
neurological diseases such as Alzheimer’s disease and 
Parkinson’s disease. However, NGF has a low 
permeability through the BBB following intravenous 
administration39. 
Quantitative methods  
Quantitative methods to study BBB nanoparticle uptake in 
vivo, involve determination of pharmacokinetic (PK) 
parameters, and biodistribution studies. For both of these 
studies either the particle itself or an entrapped compound 
is labeled. Most commonly, radioisotopes like 3H, 14C or 
125I are used. Alternatively, the entrapped compound is 
quantified by HPLC. 
Pharmacokinetic parameters  
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In most brain targeting studies, the nanoparticles are 
administered intravenously. The goal of a pharmacokinetic 
study is to assess the fraction of the administered dose that 
is distributed to the brain or is excreted from the body55. 
Nanoparticle and/or drug concentrations are measured in 
the blood (plasma) and in the brain at several time points 
after administration. From these measurements, the area 
under the concentration–time curve (AUC) can be obtained 
for both blood and brain. Pharmacokinetic models quantify 
the rate and extent of the distribution by mathematically 
analyzing these data. In this way,a number of PK 
parameters can be obtained. Commonly, several of these 
parameters are determined for either blood 43,47, brain or 
both41,42. Other organs can also be included in the PK 
study51. In current brain targeting studies, the most widely 
determined PK parameters in both blood and brain are: 
- Cmax: peak concentration  
- Tmax: time to reach peak concentration  
- AUC: area under the concentration–time curve, from the 
time of injection (t=0) to a determined time point t 
(AUC(0→t)) or extrapolated to infinity (AUC(0→∞)).  
- Half-life (t1/2): time it takes for 50% to be eliminated.  
- Mean Residence Time (MRT): the average time a 
compound remains in the blood or Brain 
Biodistribution studies  
For biodistribution studies, the nanoparticles are usually 
administered intravenously. After administration, the 
animals are sacrificed at a specific time point, or 
preferably at several time points. The brain is taken out, 
along with some of the major organs where the particles 
are likely to end up, including liver and spleen. 
Conclusion and future prospects  
In recent brain targeting studies involving nanoparticles, a 
wide range of approaches has been used by researchers to 
determine the extent, rate, and effect of drug and 
nanoparticle uptake into the brain. Choosing the right 
method depends on whether you want to obtain 
quantitative uptake values, visualize the uptake 
mechanism, or test a drug effect. Each technique has its 
own advantages and disadvantages, which should be 
considered before experiments are started. Many 
parameters like administration route, sampling time points, 
and the way in which the data are presented should be 
taken into account. Many studies have shown that 
nanoparticles can reach the brain. Within the brain 
microenvironment, targeting of nanoparticles starts with 
binding and uptake of the particles into the endothelial 
cells. By using techniques such as brain capillary depletion 
or electron microscopy, it can be shown that particles have 
crossed the endothelial barrier, and reached the brain 
parenchyma. However, the intracellular fate of 
nanoparticles in vivooften remains unclear. This is due to 
limitations of in vivo detection methods and techniques. 
Therefore, intracellular processes such as endocytotic 
mechanisms currently have to be studied in vitro56,57, in an 
artificial environment. Progress in the field of in vivo 
detection methods is ongoing58,59. In the future, faster and 
more sensitive detection methods are required to study 
uptake and trafficking of nanoparticles within the brain.
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